ARQT - Arcutis Biotherapeutics, Inc.
IEX Last Trade
14.71
-0.120 -0.816%
Share volume: 24,697
Last Updated: Fri 27 Dec 2024 05:30:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$14.83
-0.12
-0.81%
Fundamental analysis
25%
Profitability
25%
Dept financing
16%
Liquidity
75%
Performance
15%
Performance
5 Days
0.13%
1 Month
30.23%
3 Months
63.65%
6 Months
61.36%
1 Year
383.55%
2 Year
4.83%
Key data
Stock price
$14.71
DAY RANGE
$14.20 - $15.01
52 WEEK RANGE
$3.32 - $15.79
52 WEEK CHANGE
$354.24
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Todd F. Watanabe
Region: US
Website: arcutis.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arcutis.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.
Recent news